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Background. Transforming growth factor-b (TGF-b) modu-
lates immune/inflammatory cells, promotes extracellular matrix
(ECM) accumulation, and is increased in fibrotic organs. Here
we report the effects of administering a puromycin aminonu-
cleoside nephropathy (PAN)-specific TGF-b neutralizing anti-
body on glomerulosclerosis in vivo.
Methods. Adult male Sprague-Dawley rats underwent
uninephrectomy (Nx) followed by intraperitoneal PAN at
weeks 2, 6, 7 and 8. Rats were treated with either high (5 mg/kg
body weight) (N = 9) or low (0.5 mg/kg body weight) (N = 7)
dose TGF-b antibody intraperitoneally three times weekly un-
til sacrifice at week 10. A PAN untreated control group (N = 7)
was dosed with an isotype specific, null antibody. The nephrec-
tomy samples were studied as normal kidney control (NL) (N =
5). Rats undergoing left kidney Nx (N = 5) only were also in-
cluded as age-matched control. Renal function and morphology
were assessed, and molecular studies performed.
Results. Systolic blood pressure was increased in parallel over
time in all groups (at 10 weeks, control 137 ± 10 mm Hg; high
129 ± 4 mm Hg; low 137 ± 3 mm Hg) (P = NS). Both TGF-b
antibody treatments decreased renal cortex mRNA expressions
similarly for TGF-b1, TGF-b2, and collagen III (TGF-b1, con-
trol 0.36 ± 0.02 mm Hg; high 0.19 ± 0.01 mm Hg; low 0.19 ±
0.02 mm Hg; P < 0.01 low and high vs. control; TGF-b2, con-
trol 0.38 ± 0.03 mm Hg; high 0.19 ± 0.02 mm Hg; low 0.20 ±
0.03 mm Hg; P < 0.01 low and high vs. control; and collagen
III, control 0.33 ± 0.01 mm Hg; high 0.14 ± 0.01 mm Hg; low
0.19 ± 0.01 mm Hg; P < 0.01 low and high vs. control; P <
0.05 low vs. high, data expressed as mRNA normalized density
units vs. 18S RNA). However, only low dose TGF-b antibody
improved renal function and sclerosis measured by serum crea-
tinine and creatinine clearance (serum creatinine, control 2.3 ±
0.5 mg/dL; high 2.5 ± 0.5 mg/dL; low 0.8 ± 0.1 mg/dL; P < 0.05
low vs. control and high; creatinine clearance, control 0.44 ±
0.11 mL/min; high 0.70 ± 0.26 mL/min; low 1.34 ± 0.30 mL/min;
P < 0.05 low vs. control, P = NS vs. high). In parallel, sclerosis
index (0 to 4+ scale) was improved in low dose (control 2.67 ±
0.27; high 2.37 ± 0.30; low 1.78 ± 0.24; P < 0.05 low vs. control).
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This improved function and structure was linked to decreased
glomerular infiltrating macrophages (0 to 4+ score, control
2.3 ± 0.2; high 1.8 ± 0.4; low 0.8 ± 0.1; P < 0.01 low vs.
control; P < 0.05 low vs. high; P = NS high vs. control).
Further, plasminogen activator inhibitor-1 (PAI-1) mRNA
expression in renal cortex was attenuated after low dose
TGF-b antibody treatment compared to control and high
dose group (PAI-1/glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA ratio, NL 0.18 ± 0.003; control 0.45 ± 0.03;
high 0.40 ± 0.04; low 0.23 ± 0.01; P < 0.05 low vs. control
and high). Matrix metalloproteinase-9 (MMP-9) activity was
maintained at higher levels in kidneys of the low dose TGF-b
antibody-treated group.
Conclusion. These results show an in vivo dose-response with
an agent that blocks the biologic activity of TGF-b . Higher dose
of TGF-b antibody was without beneficial effect, suggesting that
TGF-b–mediated effects on PAI-1 and macrophage influx are
bimodal and closely regulated. Given that both antibody doses
reduced the expression of TGF-b isoforms and collagen III pro-
duction, but only low dose ameliorated histologic sclerosis, it
appears that pharmacologic effects of anti-TGF-b antibody on
matrix synthesis and degradation are not equivalent.
Progressive accumulation of extracellular matrix
(ECM) is a main cause of chronic renal disease in both an-
imals and humans [1], which is characterized by glomeru-
losclerosis, tubulointerstitial fibrosis and vascular
sclerosis. Transforming growth factor-b (TGF-b) has
been implicated as a key molecule in fibrosis.
The TGF-b family consists of three closely related iso-
forms (TGF-b1, 2, and 3) with important roles in modula-
tion of inflammatory cell function, growth inhibition and
differentiation, and control of ECM accumulation [2].
There is increasing evidence that chronic overexpression
of TGF-b is a characteristic of organ fibrosis and in partic-
ular renal fibrosis. TGF-b has been implicated in various
models of renal fibrosis, including the 5/6 nephrectomy
model [3], puromycin aminonucleoside nephrosis (PAN)
[4, 5], unilateral ureteral obstruction (UUO) [6], and
aging [7]. TGF-b is also tightly linked to the development
of diabetic nephropathy [8].
Overexpression of TGF-b1 in rat glomeruli by in vivo
gene transfer is associated with accumulation of ECM
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[9]. Increased TGF-b promotes this ECM accumulation,
both by increasing ECM production and possibly by
decreasing its degradation, in part by induction of plas-
minogen activator inhibitor-1 (PAI-1) [10, 11]. Both
platelet-derived growth factor (PDGF) and angiotensin
II (Ang II) increase TGF-b , and Ang II also promotes
conversion of TGF-b to its active form. Maneuvers
that inhibit Ang II also decrease TGF-b and fibrosis.
Treatment with angiotensin I-converting enzyme (ACE)
inhibitor or Ang II type 1 receptor antagonist in
the anti-Thy 1.1 glomerulonephritis rat model reduced
TGF-b overexpression and ECM accumulation [12]. Fur-
thermore, therapeutic strategies to block TGF-b1 with
either a natural inhibitor of TGF-b or antiserum against
TGF-b in this model attenuated the increase in matrix
synthesis [13, 14]. In the present study, we tested the
effects of low and high doses of anti-TGF-b antibodies
on glomerulosclerosis in a PAN model, characterized by
early marked proteinuria, followed by apparent recov-
ery before progressive sclerosis and lower level protein-
uria ensue. We aimed to examine effects of antagonizing
TGF-b in the early period of sclerosis, after the disease
process has commenced.
METHODS
Experimental design and animals
Adult male Sprague-Dawley rats (250 to 300 g, Charles
River, TN, USA) were studied. Rats were housed un-
der normal conditions with a 12-hour light/dark cycle,
at 70◦F with 40% humidity and 12 air exchanges/hour
and received standard rat powdered diet (Purina Ro-
dent “5001” meal, 23.4% protein, 4.5% fat, 6.0% fiber,
0.40% sodium) (Tusculum Feed Center, Nashville, TN,
USA) and water ad libitum. Under sodium pentobarbi-
tal (nembutal, 50 mg/kg body weight, intraperitoneally.)
anesthesia, rats underwent left kidney uninephrectomy
(Nx) followed by PAN (Sigma Chemical Co., St. Louis,
MO, USA) injections intraperitoneally at week 2 (100
mg/kg body weight) with subsequent doses of 40 mg/kg
body weight at weeks 6, 7, and 8. The nephrectomy sam-
ples were studied as normal kidney control (NL) (N =
5). Rats that underwent left kidney Nx only were stud-
ied as age-matched control (N = 5). Monoclonal anti-
TGF-b antibody (1D11) and isotype-matched irrelevant
control antibody (13C4) were provided by the Genzyme
Corp. (Framingham, MA, USA). PAN rats were then di-
vided into three groups and treated from week 6 as fol-
lows: control antibody (N = 7, 13C4 IgG1, 5 mg/kg body
weight); high dose anti-TGF-b antibody (N = 9, 1D11,
5 mg/kg body weight); low dose anti-TGF-b antibody
(N = 7, 1D11, 0.5 mg/kg body weight). The doses of anti-
TGF-b antibody were chosen based on biologic activ-
ity of inhibition of TGF-b in mouse without producing
histopathology in any organs of the body [6]. Antibody
was administered intraperitoneally three times a week
for 5 weeks. Animals were monitored with renal func-
tional assessment (see below) and sacrificed at week 10
and kidneys were harvested for analysis of morphologic
and molecular parameters.
Analysis of kidney function
Systolic blood pressure and 24-hour urinary protein
were assessed at weeks 0, 4, 8, and 10. Systolic blood pres-
sure was measured using tail-cuff plethysmography in
unanesthesized prewarmed trained rats at ambient tem-
perature of 29◦C. Individual rats were placed in metabolic
cages for 24-hour urine collection. Urinary protein was
measured using the sulfosalicylic acid (SSA) method
[15]. Serum and urinary creatinine was measured using
an Astra Autoanalyzer (Beckman Instruments, Fuller-
ton, CA, USA). Serum creatinine clearance was calcu-
lated using serum level and 24-hour urinary creatinine
concentration.
Structural analyses
Kidney tissue from rats was immersion-fixed in 4%
paraformaldehyde/phosphate-buffered saline (PBS) so-
lution, routinely processed, and 4 lm sections were
stained with periodic acid-Schiff (PAS) and Masson’s
trichrome. Immunohistochemistry and in situ hybridiza-
tion studies were performed (see below).
A semiquantitative score [sclerosis index (SI)] was
used to evaluate the degree and extent of glomerular
sclerosis. Severity of sclerosis for each glomerulus was
graded from 0 to 4+ as follows: 0 represents no lesion,
1+ sclerosis of <25% of the glomerulus, while 2+, 3+,
and 4+ represent sclerosis of 25% to 50%, 50% to 75%,
and >75% of the glomerulus, respectively. A whole kid-
ney average sclerosis index was obtained by averaging
scores from all glomeruli on one section. On average,
more than 100 glomeruli were assessed per rat. Tubuloin-
terstitial fibrosis was evaluated qualitatively on Masson’s
trichrome stained section. All sections were examined
without knowledge of the treatment protocol.
Preparation of riboprobes
To generate probes, reverse transcription-polymerase
chain reaction (RT-PCR) was done on total RNA from
normal rat kidneys using synthesized oligonucleotide
primers that are complementary to the collagen type
III cDNA sequence [16], TGF-b1 cDNA sequence
[17], and TGF-b2 cDNA sequence [18]. Linearized
cDNA was transcribed in vitro using the Maxiscript kit
(Ambion, Austin, TX, USA) according to the man-
ufacturer’s instructions. T7 polymerase and [32P] uri-
dine triphosphate (UTP) (3000 Ci/mmol) (Dupont-NEN,
Boston, MA, USA) were included in the reaction
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mixture to generate [32P]-labeled riboprobes. The reac-
tion mixture was incubated for 60 minutes at 37◦C and
then the DNA template was removed by digestion with
0.5 U RNase-free DNase. Full-length probes were pu-
rified from the transcription reaction by electrophoresis
on 6% polyacrylamide/Tris/borate/EDTA (TBE) gel, fol-
lowed by autoradiography, excision from the gel band and
passive diffusion into probe elution buffer from Maxis-
cript kit (Ambion) overnight at 37◦C. The activity of the
probe was quantified by scintillation counting.
Ribonuclease protection assays
Total RNA from renal cortex was obtained using
the RNAqueous kit (Ambion). Ribonuclease protec-
tion assay was performed using the HybSpeed RPA kit
(Ambion) according to the manufacturer’s instructions.
Briefly, radiolabeled antisense RNA probes for TGF-b1,
TGF-b2, and collagen III were combined and hybridized
with 10 ug of total RNA from each kidney sample.
A probe for 18S RNA (Ambion) was also included
in each hybridization mixture to normalize for total
RNA in individual samples. For negative control, yeast
RNA alone was combined with probes. Digestion with
RnaseA/RnaseT1 mix was performed to degrade un-
hybridized RNAs. Hybridized RNA protected from di-
gestion was resolved by electrophoresis and visualized
by using BAS-1500 phosphoimager (Fujifilm, Tokyo,
Japan). Bands on the phosphoimager representing
TGF-b1, TGF-b2, and collagen III, genes were quanti-
fied using Mac BAS Version 2.4 software. In all samples,
the expression of each gene was corrected by dividing
probe-specific signal by that obtained for the housekeep-
ing gene.
Northern blot hybridization
Total RNA from renal cortex was extracted by
Trizol reagent (Gibco Life Technologies, Grand Island,
NY, USA). Twenty micrograms of total RNA were loaded
and fractionated by electrophoresis in 1% agarose gel
and transferred to a nylon membrane. Mouse PAI-1
cDNA was labeled with [32P] deoxycytidimine triphos-
phate (dCTP) and hybridization was performed as de-
scribed previously [7]. The ratio of specific message to
the housekeeping gene GAPDH was used to quantify
expression for each tissue sample.
PAI-1 in situ hybridization and immunohistochemistry
[35S]-labeled sense and antisense riboprobes for PAI-1
were prepared as previously described [7] by transcrip-
tion of the pCRTM II plasmid (Invitrogen, Carlsbad, CA,
USA) with insertion of cDNA fragment by SP6 or T7
RNA polymerase (Ambion). Sections were dewaxed in
xylene, hydrated in graded ethanols, and then fixed in
4% paraformaldehyde. After treatment by proteinase
K and triethanolamine/acetic anhydride, sections were
dehydrated in ethanol and air-dried. Hybridization was
done in buffer [50% formamide, 10% dextran sulfate,
8 mmol/L dithiothreitol (DTT), 0.2 mg/mL tRNA,
300 mmol/L NaCl, 10 mmol/L Tris-HCl, 5 mmol/L
ethylenediaminetetraacetic acid (EDTA), 0.02%
polyvinylpyrolidone, 0.02% Ficoll, and 0.02% bovine
serum albumin (BSA)] overnight at 50◦C. Sections were
washed and then dehydrated in ethanol and air-dried,
dipped in photographic emulsion and exposed at 4◦C for
14 days. The sections were developed with D-19 devel-
oper (Kodak, Rochester, NY, USA) and counterstained
with toluidine blue. Control in situ hybridization was
done with sense probes.
For immunostaining, tissue was fixed in 4%
paraformaldehyde overnight at 4◦C, routinely processed
and embedded in paraffin. Four micrometer sections
were treated with 3% hydrogen peroxidase 10 minutes,
exposed to Power Block (BioGenex Laboratories, San
Ramon, CA, USA) for 45 minutes, incubated with
rabbit antirat PAI-1 antibody (American Diagnostica,
Inc., Greenwich, CT, USA) overnight, and rinsed twice
with PBS. Biotinylated goat antirabbit Ig (BioGenex
Laboratories) was added and incubated for 45 minutes,
followed by peroxidase-conjugated streptavidin for 45
minutes. After rinsing ×3 with PBS, diaminobenzidene
was added as a chromagen. Slides were counterstained
with hematoxylin. PAI-1 glomerular expression was
evaluated by a semiquantitative score. Scores of 0
to 4 represent negative, trace, <10%, 10% to 25%,
and >25% staining, respectively, in each glomerulus.
Negative controls without the primary antibody were
done at the same time, and showed no staining.
Collagen content
Total collagen content was measured as described pre-
viously [7]. Briefly, renal cortex was isolated, frozen,
and collagen content was calculated from the concen-
tration of hydroxyproline and proline, measured as their
phenylisothiocyanate derivatives by reverse-phase high-
performance liquid chromatography.
Detection of infiltrating macrophages
Macrophages were detected with mouse mono-
clonal antibody ED1 (BioSource International, Camar-
illo, CA, USA), followed by biotinylated goat anti-
mouse IgG (Innogenex, San Ramon, CA, USA) for
30 minutes and alkaline phosphatase-streptavidin con-
jugate (Innogenex) for 30 minutes. Sections were de-
veloped with Sigma fast red TR/Naphthol AS-MX
(Sigma Chemical Co.) for 5 minutes, then coun-
terstained and coverslipped. Negative control with
nonspecific serum from the species of primary antibody
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Table 1. General characteristics of the puromycin aminonucleoside (PAN) modela
Week 0 Week 4 Week 8 Week 10
Control High Lowel Control High Low Control High Low Control High Low
Body weight g 257 ± 4 258 ± 3 256 ± 3 301 ± 5 300 ± 5 296 ± 11 318 ± 15 308 ± 10 386 ± 7b 267 ± 7 281 ± 15 346 ± 17b
Mean arterial 115 ± 2 113 ± 5 111 ± 4 143 ± 7 148 ± 4 148 ± 4 161 ± 7 153 ± 6 155 ± 3 137 ± 10 129 ± 4 137 ± 3
pressure
mmHg
Total urine 0.3 ± 0.1 0.7 ± 0.1 0.9 ± 0.1 29 ± 3 24 ± 2 30 ± 3 78 ± 5 74 ± 8 97 ± 4 70 ± 10 78 ± 12 127 ± 16b
protein
mg/24 hours
Urinary protein/ 0.06 ± 0.01 0.1 ± 0.02 0.1 ± 0.02 3.5 ± 0.5 3.4 ± 0.3 4.8 ± 0.5 7.6 ± 0.5 6.4 ± 1.1 7.2 ± 0.7 14.4 ± 2.2 13.6 ± 3.3 13.3 ± 1.7
creatinine
aPAN rats were treated for 5 weeks with either control lgG (Control), high or low dose of neutralizing anti-transforming growth factor-b (TGF-b) antibody. Urinary
protein/creatinine ratio of protein to creatinine in 24-hour urine samples.
bP < 0.01 vs. time-matched control and high.
instead of specific antibody showed no staining. Glomeru-
lar macrophages were graded by a semiquantitative score.
Scores of 0 to 4 represent negative, <3, 3 to 9, 10 to 20,
and >20 macrophages per glomeruli, respectively.
Gelatin zymography
Gelatin zymograms of isolated tissues were performed
as previously described [19]. Briefly, freshly isolated kid-
ney cortex was pulverized in liquid nitrogen, transferred
to lysis buffer (20 mmol/L Tris-HCl, pH. 7.4, 150 mmol/L
NaCl, 10 mmol/L EDTA, 10 mmol/L benzamidine HCl,
0.02% sodium azide, 0.1% Triton X-100, 0.02% Tween
20, 2 mmol/L phenylmethylsulfonyl fluoride, 0.5 mmol/L
leupeptin, and 5 ug/mL aprotin). The protein concen-
tration of the kidney extracts was determined (BioRad
Protein Assay, BioRad, Richmond, CA, USA). Pro-
teins (5 lg/sample) were loaded on 10% sodium dode-
cyl sulfate (SDS)-polyacrylamide gels containing gelatin
(1 mg/mL), and electrophoresed at 10 mA for 3 hours
under nonreducing conditions. Gel proteins were rena-
tured in 50 mmol/L Tris, pH 7.5/0,1 mol/L NaCl/2.5%
Triton X-100 for 2 hours at room temperature, washed
briefly with water, and then incubated for 17 hours in
50 mmol/L Tris/10 mmol/L CaCl2/0.02% NaN3. Gels were
stained with Coomassie blue and destained in 5% acetic
acid/10% methanol. The zymograms were digitized and
the size-fractionated banding pattern, which indicates
matrix metalloproteinase (MMP) proteolytic activity,
was determined by quantitative image analysis (Gel Pro
Analyzer; Media Cybernetics, Silver Spring, MD, USA).
Statistical analysis
Results are expressed as mean ± standard error of
the mean (SEM). Statistical difference was assessed by
a single-factor variance (ANOVA) followed by unpaired
t test as appropriate. Nonparametric data were compared
by Mann-Whitney U test. A P value < 0.05 was consid-
ered to be significant.
RESULTS
Renal functional changes
Body weight gain was greater in low dose anti-TGF-b
antibody PAN rats compared to that seen in control and
high dose anti-TGF-b antibody groups (Table 1). Sys-
tolic blood pressure was increased in parallel over time
in all groups (Table 1). Control and high dose anti-TGF-b
antibody treated rats developed renal insufficiency, evi-
dent by elevated serum creatinine and reduced creati-
nine clearance compared to normal rats (serum creatitine
0.3 ± 0 mg/dL, creatinine clearance 1.4 ± 0.2 mL/min).
Treatment with low dose anti-TGF-b antibody decreased
the serum creatinine and improved renal function (serum
creatinine, control 2.3 ± 0.5 mg/dL; high 2.5 ± 0.5 mg/dL;
low 0.8 ± 0.1 mg/dL; P < 0.05 low vs. control and high;
creatinine clearance, control 0.44 ± 0.11 mL/min; high
0.70 ± 0.26 mL/min; low 1.34 ± 0.30 mL/min; P < 0.05
low vs. control; P = NS vs. high) (Fig. 1). Proteinuria
developed in PAN rats after 4 weeks and significantly
increased over time in controls (Table 1). Neither anti-
TGF-b antibody treatments had beneficial effect on the
development of proteinuria, whether expressed as urine
protein/creatinine ratios or 24-hour values (Table 1).
Renal morphologic changes
All control PAN rats developed glomerulosclero-
sis, tubular atrophy, dilation and interstitial fibrosis by
10 weeks. Surprisingly, high-dose anti-TGF-b antibody
treatment did not affect the course of progression of
glomerulosclerosis and tubulointerstitial fibrosis, and
showed kidney lesions similar to control rats. However,
treatment with low dose anti-TGF-b antibody signifi-
cantly ameliorated kidney sclerosis and fibrosis (SI 0 to
4+ scale: NL 0; control 2.67 ± 0.27; high 2.37 ± 0.30; low
1.78 ± 0.24; P < 0.05 low vs. control; P = NS high vs.
control) (Fig. 2). The improved function and structure by
low dose anti-TGF-b antibody was linked to decreased
glomerular infiltrating macrophages (GIM) (GIM, 0 to
4+ score: NL 0; control 2.3 ± 0.2; high 1.8 ± 0.4; low
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Fig. 1. Renal function in puromycin aminonucleoside nephropathy
(PAN) rats. Serum creatinine and creatinine clearance were improved
by low dose, but not high dose of anti-transforming growth factor-b
(TGF-b) antibody (Ab).
0.8 ± 0.1; P < 0.01 low vs. control; P < 0.05 low vs. high;
P = NS high vs. control) (Fig. 3).
Collagen content
Collagen in renal cortex, expressed as percentage of
total protein, was low in kidneys of age-matched rats
with Nx only (% collagen/total protein, 6.1 ± 1.0). Colla-
gen content increased in the PAN control group and was
numerically decreased with TGF-b antibody treatments,
especially in rats receiving low dose TGF-b antibody
treatments (control 12.5 ± 2.7; high 11.3 ± 1.5; low
10.3 ± 0.7).
Renal gene expressions
Both anti-TGF-b antibody treatments decreased re-
nal cortex mRNA expressions similarly for TGF-b1,
TGF-b2, and collagen III (TGF-b1, control 0.36 ± 0.02;
high 0.19 ± 0.01; low 0.19 ± 0.02; P < 0.01 low and high
vs. control; TGF-b2, control 0.38 ± 0.03; high 0.19 ± 0.02;
low 0.20 ± 0.03; P < 0.01 low and high vs. control; colla-
gen III, control 0.33 ± 0.01; high 0.14 ± 0.01; low 0.19 ±
0.01; P < 0.01 low and high vs. control; P < 0.05 low vs.
high) (Fig. 4).
PAI-1 mRNA and protein expression
PAI-1 mRNA expression in renal cortex assessed by
Northern blot analysis was attenuated after low dose anti-
TGF-b antibody treatment compared to control and high
dose (P < 0.05 low vs. control and high) (Fig. 5). In situ
hybridization revealed no PAI-1 mRNA detected in nor-
mal rat kidney (Fig. 6A), contrasting high level of PAI-1
mRNA expression in control and high dose anti-TGF-
b antibody-treated rat kidneys (Fig. 6B and C). Strong
PAI-1 mRNA signals were detected primarily in glomeru-
lar cells (most likely visceral epithelial, mesangial, and
endothelial cells), interstitial cells, and some tubular ep-
ithelial cells. Low dose anti-TGF-b antibody treatment
reduced PAI-1 mRNA expression in glomerular cells,
but not in glomerular parietal epithelial cells (Fig. 6D).
Trace PAI-1 protein expression, detected by immuno-
histochemistry, was seen in glomerular parietal epithe-
lial cells in normal rat kidney (Fig. 6E). Glomerular
PAI-1 protein expression level was numerically lower,
albeit not significant, after low dose anti-TGF-b anti-
body treatment (Fig. 6H) compared to control (Fig. 6F)
and high dose (Fig. 6G) (PAI-1 immunostaining scor-
ing, control 3.13 ± 0.29; high 3.00 ± 0.32; low 2.48 ±
0.26; low vs. control and high, P = NS). However, more
strong and diffuse glomerular PAI-1 immunostaining was
present in control and high dose groups. The percentage
of glomeruli with intense PAI-1 immunostaining (score
of 4) was greater in control and high dose verse low
dose (control 56%, high 57%, and low 29%). In addi-
tion, the pattern of glomerular PAI-1 protein expression
was parallel to the in situ results, with enhanced parietal
epithelial cell and less glomerular cell staining in low dose
anti-TGF-b antibody-treated rats versus control and high
dose.
MMP-2 and MMP-9 activity
Normal rat kidneys had high levels of active
MMP-9. Active MMP-9 levels were completely inhib-
ited in control PAN animals. MMP-9 activity was main-
tained at higher levels in PAN rats treated with low dose
anti-TGF-b antibody compared to PAN rats treated with
high dose anti-TGF-b antibody (Fig. 7A and B). MMP-2
showed a different expression pattern. Active MMP-2
levels were low in normal rat kidneys, increased in con-
trol PAN rats, and decreased to similar levels in the two
TGF-b antibody treatment groups (Fig. 7A and C).
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Fig. 2. Histopathologic changes in puromycin aminonucleoside
nephropathy (PAN) rat kidneys. (Upper panel) Treatment with low
dose anti-transforming growth factor-b (TGF-b) antibody (Ab) ame-
liorated glomerulosclerosis, whereas the higher dose did not. (Bottom
panel) Normal rat kidney (A). Glomerulosclerosis and tubulointersti-
tial fibrosis were similar in PAN control (B) and high dose anti-TGF-b
antibody (C) rats. Treatment with low dose anti-TGF-b antibody de-
creased glomerulosclerosis with proportional changes in tubulointersti-
tial injury (D) (Masson’s trichrome stain, 100×).
DISCUSSION
PAN nephrosis is an experimental model with initial
nephrotic range proteinuria followed by apparent remis-
sion, with subsequent development of focal segmental
glomerulosclerosis (FSGS) and lower grade proteinuria
[20]. The initial target for PAN is the podocyte, and the
PAN model thus resembles many human chronic renal
diseases. The current study evaluated the role of TGF-b
in the development of proteinuria, glomerulosclerosis,
and tubulointerstitial fibrosis in this model by assessing
the response to chronic treatment with neutralizing pan-
TGF-b antibody.
The beneficial effects of anti-TGF-b antibody treat-
ment in renal fibrosis have been seen in vitro and in vivo
0
1
2
3
G
lo
m
er
ul
ar
 m
ac
ro
ph
ag
es
, 0
-4
 s
co
re
ControlNL
Ab Anti-TGF-β Ab
High Low
P < 0.01
P = NS P < 0.01
Fig. 3. Macrophage infiltration in kidneys in puromycin aminonucleo-
side nephropathy (PAN) rats. (Upper panel) Glomerular macrophages
were significantly decreased by low dose anti-transforming growth
factor-b (TGF-b) antibody (Ab). (Bottom panel) There were no
macrophages detected in glomeruli from normal kidney (A). Glomeru-
lar macrophage infiltration was prominent in high dose anti-TGF-b an-
tibody rats (C), similar to control (B), but was significantly decreased
by low dose anti-TGF-b antibody (D) (monoclonal ED1 antibody im-
munostaining, 400×).
[14, 21]. Long-term prevention of renal insufficiency, ex-
cess matrix gene expression, and glomerular mesangial
matrix expansion in the db/db mouse model of type 2
diabetes was achieved by treatment with neutralizing
anti-TGF-b antibody [22]. Antibody to TGF-b also ame-
liorated tubular apoptosis and fibrosis in the UUO model
of interstitial fibrosis [6]. Our study confirms the efficacy
of neutralizing TGF-b , but further demonstrates an in
vivo dose response, with less effectiveness of higher doses
of neutralizing antibodies to TGF-b1. The beneficial ef-
fects on renal function and structure in this study only in
response to low dose rather than high dose TGF-b an-
tibody indicate divergent effects of low versus high dose
neutralizing TGF-b antibodies. These divergent effects of
low and high doses were linked to effects on macrophage
infiltration, implicating TGF-b’s immune effects in the
results.
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Fig. 4. Ribonuclease protection analysis of kidney mRNA levels. Trans-
forming growth factor-b (TGF-b1) (A), TGF-b2 (B), and collagen III
(Col III) (C) mRNA from puromycin aminonucleoside nephropathy
(PAN) rat kidneys are expressed as relative arbitary density units in
control, high, and low dose anti-TGF-b antibody (Ab)-treated rats.
In addition to profibrotic actions, TGF-bs are also
potent immunosuppressants capable of inducing T-cell
apoptosis, mediating antigen expression, regulating the
development of antigen-presenting cells, and inhibiting
the proliferation of hematopoeitic progenitor cells
[23–26]. The importance of TGF-b1 in regulation of im-
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Fig. 5. Quantitation of plasminogen activator inhibitor-1 (PAI-1)
mRNA expression by Northern blot. PAI-1 mRNA expression was de-
creased in kidney cortex in low dose anti-transforming growth factor-b
(TGF-b) antibody (Ab) vs. control and high dose anti-TGF-b antibody-
treated groups.
mune/inflammatory cell infiltrate is well illustrated in the
TGF-b1 knockout mice [27], which develop widespread
systemic inflammation and autoantibody formation.
The result from TGF-b2 knockout mice is dramatically
different in this regard, with only a mild development
defect [28]. TGF-b2’s effects in renal diseases have been
recognized. TGF-b2 is increased in Heyman nephritis, a
model of membranous nephropathy [29]. In obstructive
nephropathy in rats, TGF-b2 is up-regulated in the acute
stage, while both TGF-b1 and TGF-b3 are increased
in the chronic stage [30]. A direct link of TGF-b2 with
renal fibrosis was demonstrated recently in mice treated
with human recombinant TGF-b2 [31]. In the current
study, although synthesis of profibrotic factors (collagen
III, TGF-b1, and TGF-b2 mRNAs) was inhibited by
high dose anti-TGF-b antibody, there was no resulting
amelioration of fibrosis. We propose that dampened im-
munosuppression function resulting from this high dose
anti-TGF-b antibody may have permitted robust infil-
tration of macrophages in the kidney, which in turn con-
tributed to the persistence of fibrosis. Thus, we propose
that the dual effects of high dose anti-TGF-b antibody
on fibrosis and inflammation may explain the lack of net
benefit on fibrosis. Recent studies suggest that TGF-b1 is
produced by local fibroblasts and attracts macrophages
to the interstitium in fibrotic disorders as shown by stud-
ies of wounds in Smad3 null mice [32–34]. Decreased
TGF-b1 (and TGF-b2) levels but sustained infiltration of
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Fig. 6. Localization of plasminogen activa-
tor inhibitor-1 (PAI-1) mRNA and pro-
tein expression. No PAI-1 mRNA was de-
tected in glomeruli from normal kidney by
in situ hybridization (A). PAI-1 mRNA ex-
pression was marked in glomerular corpus-
cular cells in control (B) and in high dose
anti-transforming growth factor-b (TGF-b)
antibody (Ab)-treated rats (C), contrasting
more PAI-1 mRNA expression in parietal ep-
ithelial cells in low dose anti-TGF-b antibody
group (D). Trace PAI-1 protein expression
was seen in glomerular parietal epithelial
cells from normal kidney (E). Localization
of glomerular PAI-1 protein expression par-
allels glomerular PAI-1 mRNA expression in
the puromycin aminonucleoside nephropathy
(PAN) model, with a pattern shifted to more
parietal epithelial and less glomerular corpus-
cular cell staining in low group (H) vs. con-
trol (F) and high (G). The fibrotic, thickened
Bowman’s capsule shows strong PAI-1 im-
munostaining (H) (A, B, C, D, in situ
hybridization for PAI-1, 400×; E, F, G, H, anti-
PAI-1 immunostaining, 400×).
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Fig. 7. Matrix metalloproteinase (MMP)-2
and MMP-9 protein and activation levels. Pro-
and active MMP-2 and MMP-9 levels detected
by gelatin zymography (A). Semiquantitative
analysis of the levels of active MMP-9 (B)
and active MMP-2 (C). Abbreviations are:
TGF-b , transforming growth factor-b ; Ab, an-
tibody, NL, normal.
macrophages in the glomerulus in high dose anti-TGF-b
antibody-treated animals indicate possible distinct sig-
naling pathways for regulation of effects of TGF-b itself
versus effects on macrophages. Determination of precise
mechanisms will require further investigation.
Conversely, beneficial effects of low dose anti-TGF-b
antibody treatment on renal function and morphology
were linked to inhibition of infiltration of macrophages.
Experimental manipulations that decrease the number
of infiltrating macrophages have been shown to preserve
renal function [35]. Macrophages have diverse roles in
tissue injury, mediating repair and remodeling after in-
jury. However, persistence of activated macrophages is
tightly correlated with progressive fibrosis in the kidney
[36]. Macrophages can secrete numerous cytokines and
growth factors, including some with fibrosis-promoting
effects, such as PDGF; and inhibitors of matrix degrada-
tion, such as PAI-1 [37].
In the current study, in addition to the inhibition of
macrophage infiltration, the beneficial effects of low dose
anti-TGF-b antibody were associated with decreased
PAI-1 mRNA expression in kidney. TGF-b and PAI-1
have been intricately linked to development of fibro-
sis. PAI-1 is the major physiologic inhibitor of tissue-
type plasminogen activator (t-PA) and urokinase-type
plasminogen activator (u-PA), both of which activate
plasminogen to plasmin, thus promoting fibrinolysis and
proteolysis [38, 39]. PAI-1 is produced by multiple
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sources, including endothelium, vascular smooth mus-
cle cells, hepatocytes, platelets, mesangial cells, epithelial
cells, and macrophages. Our previous data directly linked
increased local PAI-1 expression to sites of sclerosis and
tubulointerstitial fibrosis [7, 11, 40, 41]. Recent data from
Oda et al [42] show protection in PAI-1 deficient mice
against fibrosis induced by ureteral obstruction, implicat-
ing PAI-1 in tubulointerstitial fibrosis as well as glomeru-
losclerosis. Decreased PAI-1 also decreases macrophage
infiltration in vivo, through mechanisms that have not
been completely defined.
We speculate that decreased PAI-1 mRNA expres-
sion with low dose anti-TGF-b antibody treatment is
associated with both decreased macrophages and in-
creased matrix degradation, and therefore, amelioration
of glomerulosclerosis. Major regulators of ECM degra-
dation in the glomerulus include the MMPs [43, 44].
MMP-2 and MMP-9 are a subfamily of the MMPs that
have been implicated in the development of kidney dis-
eases and play an important role in direct degradation of
ECM. MMP-2 degrades fibronectin and laminin, whereas
MMP-9 has more specificity toward types IV and V col-
lagen [43]. Down-regulation of MMP has been associ-
ated with ECM accumulation and progression of renal
diseases. Our data demonstrate relatively higher MMP-9
activity associated with lesser glomerulosclerosis. Inter-
estingly, MMP-2 activity was enhanced in kidneys with
persistent sclerosis, consistent with previous reports [45],
supporting that MMP-2 is not a major modulator of ECM
in glomerulosclerosis in this PAN model.
It should be noted that although proteinuria is linked
to progression of renal diseases, proteinuria and scle-
rosis may be dissociated, as we observed in PAN
nephrosis in our previous studies [46], and as seen in the
current study. In our previous study, differential effects
of ACE inhibitor and angiotensin receptor antagonist on
glomerular hemodynamics resulted in decreased protein-
uria only with ACE inhibitors, although both treatments
had equal effects on sclerosis. We speculate that the in-
creased urine protein in the lower dose TGF-b antibody-
treated animals may reflect hemodynamic changes and
improved glomerular filtration rate in this group.
CONCLUSION
Our data show an in vivo dose response with an anti-
body that blocks the biologic activity of TGF-b . Higher
dose of anti-TGF-b antibody was without beneficial ef-
fect on sclerosis. In contrast, lower dose anti-TGF-b
antibody significantly ameliorated fibrosis, an effect
linked to decreased macrophages and PAI-1, as well as
increased MMP-9 activity. Given that both doses reduced
the mRNA expression of TGF-b isoforms and colla-
gen III production, but only the low dose treatment de-
creased histologic sclerosis, it appears that pharmacologic
effects of anti-TGF-b antibody on matrix synthesis and
degradation are not equivalent. These results further in-
dicate that both decreased ECM synthesis, contributed
to by decreased TGF-b and macrophages, and in-
creased ECM degradation, contributed to by inhibition of
PAI-1 and increase in MMP-9 activity, underlie amelio-
ration of glomerulosclerosis. Our studies support that
inhibition of renal TGF-b may provide a valuable therapy
strategy for kidney diseases with glomerulosclerosis and
fibrosis. However, the dual effects of TGF-b on immuno-
suppression and matrix synthesis should be considered in
aiming at optimal therapeutic strategies.
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